Abstract:Background: Osteosarcoma (OS) is the most common primary malignant bone tumor in humans primarily occurring in children and adolescents. OS is an aggressive cancer and is typically classified as "immunologically cold" with the primary tumor microenvironment (TME) characterized as an immune desert. In a similar fashion to other cancers, the lack of immune recognition allows the primary disease to progress eventually resulting in metastatic disease. Prognosis for human OS patients without metastatic disease at the time of diagnosis who undergo definitive standard of care is 70% 5-year survival rate. In efforts to improve patient prognosis, more recent research efforts have been geared towards developing therapies to generate an anti-tumor immune response. One major challenge about generating an effective and sustainable immune response with tumor directed therapies is overcoming the immunosuppressive TME. One means of overcoming this challenge is by altering the immune TME through tumor ablation modalities. The overall goal of this study was to investigate the local and systemic immune responses associated with non-thermal focused ultrasound ablation (histotripsy) to determine the potential of histotripsy to serve as a novel immunomodulating treatment modality for OS. We hypothesized that histotripsy ablation of primary OS will result in a reduction in disease burden and stimulate a local and systemic pro-inflammatory immune response. Methods: We utilized a preclinical syngeneic orthotopic OS murine model and evaluated the local and systemic immune response 3-,7-,10-14-, and 21- days post histotripsy (DPH) with immunophenotyping via flow cytometry and immunohistochemistry, and differential gene expression analysis. Tumor ablation was evaluated by ultrasound immediately post ablation and for 2-weeks post ablation via MRI. Results:Tumor ablation was evident on ultrasound and MRI, and we observed a gross reduction in tumor size post ablation. Ablation resulted in significantly greater survival time compared to untreated tumor-bearing mice. Our IHC results revealed greater CD8 and CD4 cells compared to FoxP3 cells on the periphery of histotripsy ablated tumors. Our flow cytometry results indicate that at 3 DPH there was a peak in circulating pro-inflammatory monocytes, a significantly greater population of circulating CD8 T-cells at 14 DPH compared to untreated tumor-bearing mice, and a greater DC population at 14 DPH compared to the 3-and 7- DPH evaluated timepoints. Splenic memory CD4 T cell population increased over time post treatment. Conclusion: Our exciting results are promising and suggest that histotripsy ablation did alter both the local and systemic immune responses as hypothesized. Further investigations are warranted to continue determining the full potential of histotripsy ablation to serve as a novel treatment modality that targets both the primary tumor and induces immunomodulation to potentially mitigate metastatic disease. Citation Format: Alayna N Hay, Elliana Vickers, Ny Luong, Victor Lopez, Sheryl Coutermarsh-Ott, Eli Vlaisavljevich, Joanne Tuohy. A preclinical murine model investigation; Focused ultrasound ablation of osteosarcoma induces local and systemic immunomodulation [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B021.

p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death

Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma

The Role of CTLA-4 and PD-1 in Anti-Tumor Immune Response and Their Potential Efficacy Against Osteosarcoma

Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer

Abstract 3720: Utility of oncolytic virus as an immunostimulants and potential for combination therapy with ICIs

The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment In Vitro

Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus

Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity

Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus

Valproic Acid Combined with Zoledronate Enhance Γδ T Cell-Mediated Cytotoxicity Against Osteosarcoma Cells Via the Accumulation of Mevalonate Pathway Intermediates.

Oncolytic Viral Therapy in Osteosarcoma

Abstract B021: A preclinical murine model investigation; Focused ultrasound ablation of osteosarcoma induces local and systemic immunomodulation

Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses

Engineering Bimetallic Polyphenol for Mild Photothermal Osteosarcoma Therapy and Immune Microenvironment Remodeling by Activating Pyroptosis and cGAS‐STING Pathway

Abstract 1087: Synergistic mechanisms against pediatric bone sarcoma models: Trabectedin enhances oncolytic virotherapy intratumoral spread and antitumor immune activation

Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells

Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma

OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment

Oncolytic Adenoviruses Expressing Checkpoint Inhibitors for Cancer Therapy.

Translocator protein-targeted photodynamic therapy for direct and abscopal immunogenic cell death in colorectal cancer

Recombinant Oncolytic Adenovirus Expressing a Soluble PVR Elicits Long-Term Antitumor Immune Surveillance